Price
$12.12+1.93%Social Signal Score
Analyst Ratings
32 analystsRevenue
$898.00M-5.89%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel T. Scavilla
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 14,000
- Beta
- 0.85
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.57
Financials
Revenue
$898.00M-5.9%Net Income
$37.00M-60.0%EBITDA
$258.00M+22.4%Free Cash Flow
$55.00M-54.4%EPS (diluted)
$0.18-53.8%Shares Outstanding (diluted)
200.50M-15.2%Operating Expenses
$409.00MCash & Debt
$239.00MReturn of Capital
$12.00MRevenue by Segment (annual)
$3.92BDividend per Share
$0.16Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.68B | $-598.00M | $-3.00 |
| 2024 | $3.79B | $-910.00M | $-4.48 |
| 2023 | $3.96B | $-132.00M | $-0.62 |
| 2022 | $3.92B | $-950.00M | $-4.41 |
| 2021 | $4.23B | $411.00M | $1.88 |
| 2020 | $3.34B | $-73.00M | $-0.38 |
| 2019 | $4.02B | $256.00M | $1.18 |
| 2018 | $3.99B | $-1.01B | $-4.51 |
| 2017 | $3.99B | $-1.55B | $-6.86 |
| 2016 | $3.75B | $429.90M | $1.97 |
| 2015 | $2.67B | $251.20M | $1.79 |
| 2014 | $2.92B | $322.85M | $2.28 |
| 2013 | $2.95B | $313.19M | $2.20 |
| 2012 | $2.93B | $314.21M | $2.22 |
Valuation
XRAYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (4)
- Newszacks.com·18d ago·Neutral
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
View source ↗ - Newszacks.com·27d ago·Positive
XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.
View source ↗ - Newsprnewswire.com·48d ago·Positive
New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence New system completes the Surity™ portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect Hea
View source ↗ - Newsmarketbeat.com·59d ago·Negative
DENTSPLY SIRONA Q2 Earnings Call Highlights DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.32 per share
Typical surprise -3.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.52 vs $0.35beat
- Tue, May 5$0.27 vs $0.28miss
- Thu, Feb 26$0.27 vs $0.28miss
- Thu, Nov 6$0.37 vs $0.45miss
- Thu, Aug 7$0.52 vs $0.50beat
- Thu, May 8$0.43 vs $0.29beat
Estimates and results for XRAY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XRAY officers and directors.
- Bought
- $1.7m
- Sold
- $916k
12 trades
1 trade
- Hosein Clydebought
- Gladden Brian Tbought
- Mazelsky Jonathan Jaybought
- Mckeon Brian Pbought
- Holden Betsy Dbought
- Barber Michael Jbought
- Lucier Gregory Tbought
- Forbes James Dbought
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 12, 2025 (36d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 12, 2025 (35d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2022 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (18d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed May 25, 2022 (36d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed May 25, 2022 (36d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed May 6, 2022 (25d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 6, 2022 (15d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 17, 2022 (30d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 17, 2022 (30d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 17, 2022 (43d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 17, 2022 (43d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Jan 16, 2022 (44d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Jan 16, 2022 (42d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed May 21, 2019 (12d later)Buy$1,001 - $15,000
- Dean Phillipshouse · MN03 · disclosed Feb 18, 2019 (45d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.